Peptide Half-Life, Explained: Why Dosing Frequency Varies

Two peptides can target the same receptor and still call for different dosing: one daily, another weekly. The usual explanation is a single property: half-life, the time it takes for the body to clear roughly half of a dose from circulation. Understanding it demystifies why some schedules look the way they do, and why you cannot move a dose around for convenience.

What half-life measures

Half-life describes the rate of decline of a compound’s concentration in the blood. After one half-life, about half remains; after two, about a quarter; and so on. A peptide with a short half-life rises and falls quickly, so keeping it in an effective range may require frequent dosing. A long half-life means the compound lingers, allowing infrequent doses to maintain a relatively steady level.

The key idea: dosing frequency is mostly an attempt to keep concentration inside a useful window (high enough to act, not so high that side effects dominate). Half-life sets how hard that is to do.

Why peptides differ so much: the GLP-1 family

The GLP-1 system is the clearest worked example. Native GLP-1 has a half-life of about 2 minutes, because enzymes, primarily dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase, degrade it almost immediately. That makes the natural hormone useless as a drug.

Drug designers extend half-life deliberately, and the GLP-1 receptor agonists show each trick and its payoff:

Compound	Approx. half-life	Engineering
Native GLP-1	~2 minutes	none (rapidly cleaved by DPP-4)
Exenatide	~2–4 hours	Gly⁸ substitution resists DPP-4
Liraglutide	~13 hours	fatty-acid acylation → albumin binding
Semaglutide	~7 days (1 week)	acylation + Aib⁸ substitution blocking DPP-4

Semaglutide’s ~1-week half-life comes from a C18 fatty-diacid chain that reversibly binds serum albumin (riding albumin’s slow turnover) plus an Aib⁸ substitution that sterically blocks DPP-4. That is precisely why it can be dosed once weekly rather than daily.

What this means in practice

A few consequences follow directly from the pharmacology:

1. Short half-life, frequent dosing. Skipping a dose causes a real trough.
2. Long half-life, steadier levels. More forgiving of timing, but slower to clear if a problem arises. With a ~1-week half-life, semaglutide takes roughly 5 weeks (about five half-lives) to wash out after the last dose.
3. Steady state takes time. Levels usually plateau after roughly four to five half-lives of consistent dosing.

This last point explains why effects, and some side effects, can keep evolving for weeks after starting.

The takeaway

Dosing frequency is not arbitrary and rarely flexible. It is engineered around half-life to hold a compound in its effective range. The GLP-1 family makes the point cleanly: the same receptor, dosed anywhere from continuously (native, ~2 minutes) to once weekly (semaglutide, ~1 week), purely because of how each molecule resists degradation. If a schedule seems oddly specific, half-life is usually the reason, and that is a feature, not red tape.

Sources

• Glucagon-like peptide-1 and GLP-1 receptor agonists in the treatment of type 2 diabetes (Annals of Pediatric Endocrinology & Metabolism, 2017)
• Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics (Clinical Pharmacology in Drug Development, 2021)